Show Hide image

Novella Clinical takes over Prologue Research

Novella acquires the Ohio-based clinical research organisation which specialises in oncology drugs.

Novella Clinical has acquired Prologue Research, an Ohio-based clinical research organisation (CRO) that focuses exclusively on oncology drug development.

Novella Clinical and Prologue Research have been providing contract research services for biotechnology, pharmaceutical and device companies for 12 years. The acquisition will add approximately 60 staff to Novella's global base of 738 professionals, and an office located in Columbus, Ohio.

Richard Staub, president and CEO of Novella Clinical, said: "The acquisition of Prologue strengthens our oncology therapeutic franchise and is a strategic addition to our earlier announced deal this year with OSI Pharmaceuticals.

"Prologue's experience includes the management of more than 120 oncology trials across a wide variety of indications with a customer base that does not overlap with Novella Clinical's.

"With Prologue, Novella will expand its support to oncology Sponsors with the creation of a dedicated business unit focused exclusively on oncology drug development, with the objective of bringing much needed products to market to improve the lives of people with cancer."

Tom Ludlam, president and CEO of Prologue Research, said: "We are excited to be joining forces with Novella Clinical. Combining Prologue's experienced oncology team with Novella Clinical's oncology team, their infrastructure and e-based technology allows us to better serve current and future customers in the design and execution of complex oncology programs across geographic regions."